Skip to content

Transcranial magnetic stimulation for obsessive compulsive disorder

Neuronavigationally Targeted rTMS in Treatment Resistant Obsessive Compulsive Disorder

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12613000780752
Acronym
rTMS for OCD
Enrollment
19
Registered
2013-07-12
Start date
2013-10-22
Completion date
2016-02-01
Last updated
2022-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

A number of small studies have investigated the therapeutic potential of repetitive transcranial magnetic stimulation (rTMS) for OCD by stimulating an area of the frontal lobe called the DLPFC. On the whole, the results of these studies have not been encouraging. The current project aims to compare the clinical efficacy of rTMS for OCD at two promising novel treatment targets: right sided premotor cortex versus bilateral supplementary motor area. Participation in the trial involves having two MRI brain scans and four weeks of inpatient rTMS treatment in Melbourne, Australia.

Interventions

Participants will receive a 30-minute repetitive transcranial magnetic stimulation (rTMS) treatment each week day for four weeks (20 treatments in total). rTMS will be delivered with a Medtronic Magpro stimulator at 1 Hz and 120% of motor threshold in one continuous train of 30 minutes duration (1800 pulses per day).

Sponsors

Monash Alfred Psychiatry Research Centre
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Primary purpose
Treatment

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Have a DSM-IV diagnosis of an obsessive compulsive disorder. 2. Have treatment resistance as defined by a failure to respond to at least two trials of adequate dose and duration of appropriate medications (serotonin reuptake inhibitor medications or clomipramine). 3. Have had no increase or initiation of new medication therapy in the 6 weeks prior to screening.

Exclusion criteria

1. Have an unstable medical condition, neurological disorder or any history of a seizure disorder or are currently pregnant or lactating. 2. Have a current DSM IV diagnosis of substance abuse or dependence disorder, a diagnosis of a personality disorder or another axis 1 disorder except depression or another anxiety disorder. 3. Any contraindication to TMS or MRI scanning.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026